TL;DR
This paper introduces MEEA, a novel microfluidics-based enrichment and emulsion-amplification protocol, that significantly improves the resolution of airway metagenomic studies. By efficiently removing host DNA and amplifying microbial DNA, MEEA enables strain-level identification of bacteria and viruses in sputum samples, offering unprecedented insights into respiratory microbiome complexity and disease pathogenesis.
What Problem Does This Paper Address?
The human airway microbiome plays a crucial role in respiratory health and disease, but its detailed molecular composition remains largely unknown. This knowledge gap is primarily due to a major technical challenge: airway samples, like sputum, are heavily contaminated with host DNA (up to 99%). This overwhelming host signal masks the relatively small amount of microbial DNA, making it difficult to obtain sufficient microbial genetic material for comprehensive shotgun metagenomic sequencing. Existing methods often struggle to effectively remove host DNA without introducing bias or to amplify the limited microbial DNA sufficiently for deep analysis, thus hindering the ability to identify microbial species, strains, and their functional genes.
Methods
The core innovation presented is the Microfluidics-based Enrichment and Emulsion-based Whole-Genome Amplification (MEEA) protocol. This two-part approach tackles the problem head-on:
- Microfluidic Enrichment: A custom-designed, clog-free microfluidic chip is used for size-based separation. It efficiently filters out larger host cells and debris, while allowing smaller microbial cells (bacteria and viruses) to pass through. This step significantly reduces host DNA contamination.
- Emulsion-based Whole-Genome Amplification (eMDA): The enriched microbial DNA, which is often in very low quantities, is then amplified using a multiple displacement amplification (MDA) technique performed within numerous tiny emulsion droplets. This droplet-based approach ensures consistent and unbiased amplification, even from single cells, yielding microgram quantities of high-quality DNA suitable for downstream sequencing.
The authors also detail specific sample preparation steps, including a mild fixation with ethanol to protect host cells for easier depletion and a liquefaction process for viscous sputum.
Datasets
The study utilized two main types of datasets for evaluation:
- Mock Samples: These were created by mixing known microorganisms (bacteria, viruses, and fungi) and human DNA in controlled ratios. These were used to initially assess the efficiency and bias of the microfluidic enrichment and eMDA steps independently and in combination.
- Clinical Sputum Samples: Six sputum samples from patients with acute respiratory infections were collected and analyzed. These samples were used to compare the MEEA protocol against direct sequencing (without enrichment or amplification) on real-world, challenging samples.
The paper does not introduce a new benchmark dataset but rather uses clinical samples to demonstrate the efficacy of their developed protocol.
Key Insights and Ideas
- Size-based separation is key: The microfluidic chip's ability to distinguish between larger host cells and smaller microbes is fundamental to reducing host contamination.
- Emulsion amplification for consistency: Performing MDA in emulsion droplets is crucial for achieving uniform amplification across the microbial community, preventing bias towards certain species.
- Strain-level resolution is achievable: The increased depth and quality of microbial DNA obtained through MEEA allow for the identification of distinct microbial strains, which is critical for understanding disease dynamics and evolution.
- Beyond bacteria: MEEA is effective not only for bacteria but also for viruses, opening doors to a more comprehensive understanding of the airway virome.
- Prophage discovery enhanced: The improved assembly quality from MEEA data facilitates the discovery of mobile genetic elements like prophages, which can carry virulence factors.
Key Results
- Significant microbial enrichment: MEEA enabled 2 to 14 times enrichment for microbial reads in clinical sputum samples, increasing their proportion from as low as 0.99% to 14.68%-33.52% of total reads.
- Improved taxonomic profiling: MEEA identified a significantly broader range of bacterial species (416 species) compared to direct sequencing (47 species) in a typical sample, with high concordance for dominant species.
- Enhanced genome assembly: MEEA resulted in longer contigs and improved genome coverage for key species, such as S. aureus and C. gilardii, facilitating more accurate functional annotation and strain-level analysis.
- Prophage identification: The protocol led to the discovery of a novel 50 kb prophage genome within an S. aureus genome.
- Strain-level detection of viruses: MEEA successfully identified co-existing strains of HSV-1 in a patient, revealing rapid evolution of the virus.
Limitations and Future Work
- Fungi and protozoa limitations: The current microfluidic chip design is not ideal for enriching larger microbes like most fungi and protozoa, as their sizes often exceed the 5 µm cutoff.
- Residual human DNA: While significantly reduced, some residual human DNA contamination persists, estimated to originate from ruptured host cells.
- Future directions: The authors suggest that the MEEA protocol could be adapted for other complex host microbiome samples (saliva, lavage fluid, biopsies, etc.) and potentially modified for respiratory metatranscriptome sequencing to include RNA viruses and validate functional analyses. The emergence of long-read sequencing technologies like nanopore sequencing is also highlighted as a promising avenue for further improving genome assembly contiguity.
Summary updated